Table of Contents Author Guidelines Submit a Manuscript
Schizophrenia Research and Treatment
Volume 2012, Article ID 970131, 5 pages
http://dx.doi.org/10.1155/2012/970131
Research Article

Evaluation of Factors Affecting Continuous Performance Test Identical Pairs Version Score of Schizophrenic Patients in a Japanese Clinical Sample

1Department of Psychiatry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
2Department of Psychiatry, Matsuzaki Hospital, 67 Azamotosanbongi, Sanbongi-cho, Aichi, Toyohashi 441-8152, Japan

Received 13 December 2011; Accepted 1 February 2012

Academic Editor: Nakao Iwata

Copyright © 2012 Takayoshi Koide et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Lichtenstein, B. H. Yip, C. Björk et al., “Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study,” The Lancet, vol. 373, no. 9659, pp. 234–239, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Stefansson, R. A. Ophoff, S. Steinberg et al., “Common variants conferring risk of schizophrenia,” Nature, vol. 460, no. 7256, pp. 744–747, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Shi, D. F. Levinson, J. Duan et al., “Common variants on chromosome 6p22.1 are associated with schizophrenia,” Nature, vol. 460, no. 7256, pp. 753–757, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. S. M. Purcell, N. R. Wray, J. L. Stone et al., “Common polygenic variation contributes to risk of schizophrenia and bipolar disorder,” Nature, vol. 460, no. 7256, pp. 748–752, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Y. M. Ng, D. F. Levinson, S. V. Faraone et al., “Meta-analysis of 32 genome-wide linkage studies of schizophrenia,” Molecular Psychiatry, vol. 14, no. 8, pp. 774–785, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. R. E. Gur, M. E. Calkins, R. C. Gur et al., “The consortium on the genetics of schizophrenia: neurocognitive endophenotypes,” Schizophrenia Bulletin, vol. 33, no. 1, pp. 49–68, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. B. A. Cornblatt, N. J. Risch, G. Faris, D. Friedman, and L. Erlenmeyer-Kimling, “The continuous performance test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families,” Psychiatry Research, vol. 26, no. 2, pp. 223–238, 1988. View at Google Scholar · View at Scopus
  8. M. F. Green, “What are the functional consequences of neurocognitive deficits in schizophrenia?” American Journal of Psychiatry, vol. 153, no. 3, pp. 321–330, 1996. View at Google Scholar · View at Scopus
  9. M. F. Green, R. S. Kern, D. L. Braff, and J. Mintz, “Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”?” Schizophrenia Bulletin, vol. 26, no. 1, pp. 119–136, 2000. View at Google Scholar · View at Scopus
  10. M. F. Green, R. S. Kern, and R. K. Heaton, “Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS,” Schizophrenia Research, vol. 72, no. 1, pp. 41–51, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. B. A. Cornblatt and J. G. Keilp, “Impaired attention, genetics, and the pathophysiology of schizophrenia,” Schizophrenia Bulletin, vol. 20, no. 1, pp. 31–46, 1994. View at Google Scholar · View at Scopus
  12. K. S. Kendler and M. C. Neale, “Endophenotype: a conceptual analysis,” Molecular Psychiatry, vol. 15, no. 8, pp. 789–797, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. K. H. Nuechterlein, M. F. Green, R. S. Kern et al., “The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity,” American Journal of Psychiatry, vol. 165, no. 2, pp. 203–213, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Erlenmeyer-Kimling and B. A. Cornblatt, “A summary of attentional findings in the New York high-risk project,” Journal of Psychiatric Research, vol. 26, no. 4, pp. 405–426, 1992. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Inagaki and T. Inada, “Dose equivalence of psychotropic drugs. Part XX: dose equivalence of novel antipsychotics: blonanserin,” Japanese Journal of Clinical Psychopharmacology, vol. 11, pp. 887–890, 2008. View at Google Scholar
  16. A. Inagaki and T. Inada, “Dose equivalence of psychotropic drugs. Part XXII: dose equivalence of depot antipsychotics III: risperidon long-acting injection,” Japanese Journal of Clinical Psychopharmacology, vol. 13, pp. 1349–4353, 2010. View at Google Scholar
  17. S. R. Kay, A. Fiszbein, and L. A. Opler, “The positive and negative syndrome scale (PANSS) for schizophrenia,” Schizophrenia Bulletin, vol. 13, no. 2, pp. 261–276, 1987. View at Google Scholar · View at Scopus
  18. M. R. Nieuwenstein, A. Aleman, and E. H.F. De Haan, “Relationship between symptom dimensions and neurocognitive functioning in schizophrenia: a meta-analysis of WCST and CPT studies,” Journal of Psychiatric Research, vol. 35, no. 2, pp. 119–125, 2001. View at Publisher · View at Google Scholar
  19. K. E. Burdick, P. DeRosse, J. M. Kane, T. Lencz, and A. K. Malhotra, “Association of genetic variation in the MET proto-oncogene with schizophrenia and general cognitive ability,” American Journal of Psychiatry, vol. 167, no. 4, pp. 436–443, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. T. D. Cannon, “Candidate gene studies in the GWAS era: the MET proto-oncogene, neurocognition, and schizophrenia,” American Journal of Psychiatry, vol. 167, no. 4, pp. 369–372, 2010. View at Publisher · View at Google Scholar · View at Scopus